ArticleFrontiers in immunology2026
CFD
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transcriptome-wide association study (TWAS) contributes to discovering novel susceptibility genes related to diseases. Single-cell RNA sequencing (scRNA-seq) has been extensively applied to characterize cellular heterogeneity in various biological and pathological conditions. However, few studies have integrated TWAS and scRNA-seq to decode the pathogenesis of myasthenia gravis (MG) at cellular resolution. Methods: We integrated multi-omics data from GEO, genome-wide association study (GWAS) catalog, and Genotype-Tissue Expression (GTEx) databases, including scRNA-seq data, GWAS summary data, and expression quantitative trait loci. A set of risk genes genetically associated with MG were identifies using TWAS analysis. TWAS activity status across cell types in MG at single cell resolution was assessed based on these genes. Seven machine learning algorithms were performed to identify high TWAS activity related signature genes. Machine learning benchmark was incorporated to select the best model using R package "mlr3". Meanwhile, we performed scRNA-seq on peripheral blood collected from MG patients and healthy controls to generate a validation dataset. Results: scRNA-seq analysis revealed an elevated proportion of CD14 Conclusion: In summary, this study systematically delineates the important role of CFD
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.